-
2023-07-04SHH De Novo Completed Dosing of First Patient in China in Phase I Clinical Study for ATR inhibitor DN020198
-
2021-11-11SHH De Novo Completed Dosing of First Patient in China in Phase I Clinical Study for STING agonist DN015089
-
2021-07-27SHH De Novo receives approval to initiate clinical trials in China with STING agonist DN015089
-
2020-10-28SHH De Novo Completed Dosing of First Patient in China in Phase I Clinical Study for Novel TLR8 agonist DN1508052
-
2019-10-14SHH De Novo receives approval to initiate clinical trials in China with TLR8 agonist DN1508052
-
2019-09-18SHH De Novo Completed Dosing of First Patient in the US in Phase I Clinical Study for Novel TLR8 agonist DN1508052
-
2018-11-22SHH De Novo announces IND Clearance for DN1508052, a TLR8 agonist
-
2018-06-06SHH De Novo receives approval to initiate clinical trials in China with IDO1/TDO2 inhibitor DN1406131
-
2018-04-28SHH De Novo participated in the annual meeting of the AACR in 2018 and did poster exhibition
-
2018-01-05SHH De Novo submitted the IND application of DN1406131 to FDA
沪公网安备 31011502005675号